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1. Introduction
Movement disorders are considered one of the most controversial diseases when it comes to 
diagnosis, classification, and evidence-based lines of management, each case is different, and 
it can be quite challenging to get these movements under control [1].
Dystonia is a wide-spectrum disorder which affects all age groups. Etiology of dystonia 
is usually diverse; in some cases within the pediatric age group, the presence of spasticity 
can make the diagnosis more difficult. For example, cerebral palsy patients can suffer from 
dystonia and spasticity, though most of pediatric cases with cerebral palsy will suffer from 
spasticity alone. Dystonia may result from either diffuse or localized pathology of the cerebral 
cortex, brain stem, or spinal cord. Management of dystonia is challenging, and specific goals 
should be identified. Dystonia is considered one of the most disabling conditions in pediatric 
age group which may remain till adulthood, treatment is usually unsatisfactory, and patients 
will show limited response to pharmacotherapy [1].
Dystonia is a neurological disorder of patterned, involuntary, repetitive, or sustained contraction 
of antagonist group of muscles. This results in twisting movements and ends in abnormal pos-
turing. Primary dystonia is considered the most common form of dystonia encountered through 
neurology practice. Isolated dystonia usually starts during childhood years or early adolescence. 
It usually runs a progressive course with marked disability and functional impairment. Recent 
advances in genetics elaborated more than the well-known monogenic forms of isolated dysto-
nia due to DYT gene defects; the etiological spectrum is now widened with great variance in phe-
notype. Many genes which were thought to be responsible to cause certain disease were recently 
proven to be responsible for dystonia as well which results in more complex phenotype [2].
Current treatment aims to help decrease the frequency of abnormal involuntary movements, 
improve posturing, and prevent the subsequent development of contractures. This will reduce 
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pain and facilitate better quality of life. These include oral pharmacotherapy, e.g., trihexy-
phenidate (Level A Class I–II); botulinum toxin injection for cases of localized or segmental 
dystonia, e.g., cervical dystonia (Level A Class I–II); and surgical interventions like intrathecal 
baclofen pump; and deep brain stimulation (DBS) for cases with generalized dystonia who 
failed oral pharmacotherapies [3].
2. Management modalities
Intrathecal baclofen proved to be effective in progressive dystonia in selected cases. Deep 
brain stimulation is more effective in controlling primary generalized dystonia. Intracranial 
stimulation of the postero-latero-ventral region of the internal globus pallidus in patients with 
dystonia-choreoathetosis cerebral palsy significantly improved their level of functionality 
and motor abilities, reduces their pain, and improved their overall quality of life. Synergetic 
effect was proved to be highly effective in treating primary generalized dystonia where both 
surgical modalities were used and produced excellent control of dystonia. It can reach up to 
97% improvement regarding hygiene, posturing, and daily life activities [3].
Medical cannabis have been explored in a variety of medical conditions which are not con-
trolled with the current treatment modalities. Cannabidiol oil has been studied in pediatric 
cases with complex motor disorders; significant improvement in control of spasticity and 
dystonia was achieved; it was well tolerated and showed good effect on sleep pattern, pain, 
and overall quality of life [4].
3. Presentations
Dystonia has various forms of presentations; one of the popular forms is Meige’s syndrome 
or “oromandibular dystonia”; it is considered as one of the most important forms of focal 
dystonia as it may be misdiagnosed as temporomandibular joint disorder or psychogenic 
disorder which will alter the management plan and delay proper treatment. That chapter 
describing oromandibular dystonia will cover its etiology, diagnosis, and available lines of 
management. Furthermore, the consensus update will be discussed, with recent classifica-
tion of dystonia focusing on its clinical characteristics and etiology. The first focuses on the 
age of onset, body distribution, chronological pattern, coexistence of other movement disor-
ders, and other neurological manifestations. The body distribution is classified to focal, seg-
mental, multifocal, generalized, or hemi-dystonia. Associated features distinguish isolated 
dystonia in both genetic and idiopathic cases that are often resembled to as primary dystonia 
and combined dystonia. The second axis allows further division according to the presumed 
etiology.
Although dystonia is a rare condition in general population, the “pure,” primary, and isolated 
dystonia is the third most common movement disorder, after essential tremor and Parkinson’s 
disease; dystonia and associated disorders influenced a major impact on quality of life.
Dystonia - Different Prospects4
Concepts on phenomenology have also renewed with decades, considering dystonia to be a 
solely motor disorder to an increasing recognition of associated neurological or psychiatric 
features which indicate that the disorder is not purely motor. This resembles the growing 
knowledge on dystonia’s pathophysiology where the recent insights from neurophysiologic 
studies identified functional abnormalities in the basal ganglia sensorimotor network and, 
more recently, the cerebellothalamocortical pathway. Besides the well-known lack of inhibi-
tion at different nervous system levels, dystonia is specifically characterized by abnormal 
sensory feedback, maladaptive plasticity in the sensorimotor cortex, and loss of cortical sur-
round inhibition.
Bearing in mind the new classification, where the term “primary” is no more recommended, 
and the circumstance that in majority of cases it resembles the new and more precise term 
“isolated,” both terms are used in this chapter, in order to be correct when providing infor-
mation from the studies cited, fully understanding that some time and efforts are needed to 
replace completely the old terminology with the new one.
Dystonia with non-motor co-morbidities, including sleep and psychiatric disorders, cogni-
tion, as though as pain and sensory symptoms, their pathophysiological and biochemical 
mechanisms, relations with the symptomatic treating strategies for the abnormal movements, 
and specific treatment for the non-motor signs.
Many antipsychotic drugs have been used to control these comorbid conditions. Neuroleptics 
caused variety of intolerable side effects, among which drug-induced movement disorders 
could be seriously problematic. Tardive syndromes, represented by tardive dyskinesia and 
tardive dystonia, still remain challenging in many respects.
“Dystonia tarda” was a term firstly used in 1973 to define a dystonia which appeared as a 
delayed undesirable effect in patients exposed to neuroleptic drugs. Case descriptions appear 
in the literature even earlier, but a definition of the term “tardive dystonia” came from Burke 
et al. [5] who also implemented criteria for the diagnosis. The syndrome consists of invol-
untary, sustained muscle contractions, usually slow, often painful, affecting the face, neck, 
limbs, or trunk. The involuntary muscle contraction(s) often cause abnormal postures and 
twisting movements, which are often disfiguring and socially awkward.
Tardive syndromes manifest in a variety of persistent motor and sensory syndromes, mani-
festing as an adverse reaction from antidopaminergic agents or, less often, by other types 
of drugs. Tardive dyskinesia was the first to be observed, in the 1950s, typically compris-
ing rhythmic, repetitive oro-buccal-lingual involuntary movements, which however can also 
appear in the trunk, limbs, and pelvis. Later, it was also described as a distinct, frequently 
co-occurring, or independently manifesting condition. Although the term “tardive” impli-
cates a long exposure and delayed onset, tardive syndromes can actually show up even days 
after administration of the offending agent, notwithstanding that risk increases with longer 
exposure durations. Another important feature is their persistent nature, meaning that they 
persist or even worsen following discontinuation of the offending drug.
Researchers have difficulties to deal with it separately. Moreover, there is often some confu-
sion in the literature, as authors may sometimes use the term tardive dyskinesia in order to 
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refer to a variety of tardive syndromes. Much work examines tardive syndromes in general, 
and it is difficult to extract data referring specifically to tardive dystonia. Still, the distinction 
and separate examination are important, because it differs from tardive dyskinesia in respects 
of presentation, course, prognosis, and treatment; it is frequently more debilitating and treat-
ment resistant; it is associated with poorer quality of life, reduced treatment compliance, and 
psychiatric morbidity. Another task is to differentiate tardive dystonia from acute dystonia, 
emerging acutely and within days after the initial administration of anti-D2 agents, in young 
males, as well as from other types of dystonia.
In their pioneering work, Adityanjee et al. [6] had hoped that tardive dystonia together with 
tardive dyskinesia would in the future be a matter of historical interest, thanks to the advent 
of new, better antipsychotics. Twenty years later, these movement disorders are not at all 
lost, not yet forgotten. Continuing to be a serious burden, they call for better understanding, 
prompt recognition, prevention, and better treatment.
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